Dianthus Therapeutics, Inc. is a New York-based clinical-stage biotechnology firm focused on advancing innovative monoclonal antibody therapies targeting severe autoimmune and inflammatory diseases. With a robust pipeline, the company aims to address unmet medical needs through its proprietary antibody drug development programs. As it progresses through clinical trials, Dianthus positions itself as a potential leader in precision medicine for challenging health conditions, appealing to institutional investors seeking opportunities in cutting-edge biopharmaceutical solutions.